BDTT-023: Recent Advances and Research in Hemodialysis & Kidney Transplantation

UNIT C — Modalities of Modern Hemodialysis

Background: Why Standard Thrice-Weekly HD Has Limitations

• Cumulative weekly dialysis time
• Middle-molecule (500–60,000 Da) clearance (β₂-microglobulin, FGF-23, PTH fragments)
• Rate of ultrafiltration — rapid fluid removal causes intradialytic hypotension and myocardial stunning
• Retention of residual kidney function

a. Nocturnal Dialysis

• Extended duration allows slower ultrafiltration rates (preventing intradialytic hypotension and cardiovascular stress)
• Greatly increases convective and diffusive clearances of both small and middle molecules
• Enables liberalization of dietary restrictions (fluid, phosphate, potassium) due to improved clearance

• Extensive observational data showed improved blood pressure, LV mass reduction, phosphate control, and quality of life
• The Frequent Hemodialysis Network (FHN) Nocturnal Trial (RCT) compared nocturnal HD (6×/week) vs. conventional HD. The prespecified primary composite (mortality + change in LV mass or SF-36 physical component score) was not met
• However, significant improvements in secondary outcomes were demonstrated: interdialytic weight gain, blood pressure control, and predialysis phosphate levels

• Patient fear of catastrophic events while asleep (severe hypotension, needle dislodgement)
• Nurse recruitment for overnight shifts
• Need for physician availability at night

National Kidney Foundation Primer on Kidney Diseases, 8e, p. 602

b. Online Hemodiafiltration (OL-HDF) — "Online Dialysis"

• ESHOL trial (2013, n=906): OL-HDF reduced all-cause mortality by 30% and cardiovascular mortality by 45% vs. HD
• CONVINCE RCT (NEJM, 2023; PMID 37326323, n=1360): High-volume OL-HDF (≥22 L convective volume/session) significantly reduced all-cause mortality compared to high-flux HD (HR 0.77; 95% CI 0.65–0.93). A subsequent analysis also showed improved quality of life (Kidney Int 2024, PMID 39089577)
• The CONVINCE trial is now considered landmark evidence supporting OL-HDF adoption

• Superior removal of β₂-microglobulin, FGF-23, free light chains, and other middle/large molecules
• Reduced inflammation and oxidative stress
• Improved BP control and anemia management
• Associated with reduced cardiovascular hospitalizations

c. Short Daily Hemodialysis

• Mimics the continuous solute removal of functioning kidneys more closely
• Reduces the "peaks and troughs" of conventional intermittent HD (uremic toxin accumulation between sessions)
• Gradual ultrafiltration reduces hemodynamic stress

• The FHN Daily trial (Chertow et al., NEJM 2010) compared 6×/week in-center HD vs. 3×/week
• Primary composite outcome MET: Mortality + change in LV mass improved significantly
• Secondary outcomes also improved: BP, interdialytic weight gain, phosphorus, quality of life (physical component)
• However, more frequent vascular access interventions were required

1. Weekly total dialysis time
2. Ultrafiltration rate (target <10–13 mL/kg/hr)
3. Middle-molecule clearance

NKF Primer on Kidney Diseases 8e, p. 602; Brenner and Rector's The Kidney, 2-Volume Set

UNIT D — Telemedicine in Dialysis Practice

Overview

Key Applications

• Wearable sensors and dialysis machine connectivity allow real-time transmission of session data (blood pressure, weight, ultrafiltration volume, intradialytic events) to the care team
• Alerts generated for abnormal values (e.g., intradialytic hypotension, missed treatments)
• Proven to reduce hospitalizations and emergency visits in home HD patients

• Replaces routine in-person clinic visits for stable HD patients
• Video consultations used for medication adjustment, dietary counseling, vascular access review
• Particularly valuable for: home dialysis patients, rural populations, patients with transport difficulties

• Modern home HD machines (NxStage, Outset Tablo) have built-in connectivity:
  • Touch-screen guidance through treatment steps
  • Automatic data upload to the nephrologist's EMR after each session
  • Built-in alerts and error detection
• Patients can schedule virtual check-ins directly through the machine interface

• AI models predict: intradialytic hypotension episodes, missed sessions, vascular access failure, fall risk
• Precision dialysis: Big data + AI used to individualize dialysis prescriptions (ultrafiltration rate, session length, dialysate composition) rather than applying uniform protocols
• ASN AI Workgroup (2025) published a statement on "Responsible Use of AI to Improve Kidney Care"

• Remote hemodynamic monitoring during nocturnal home HD
• Automated blood-leak detectors that awaken sleeping patients
• These technologies directly address the safety barriers that have historically limited nocturnal home HD adoption

• Bioimpedance-based devices (e.g., BCM — Body Composition Monitor) can transmit fluid status data remotely, enabling individualized ultrafiltration targeting without in-person visits

Evidence Base

• A 2024 systematic review (Nefrologia 2024, Mata-Lima et al.) on remote patient monitoring in nephrology documented significant reductions in hospitalizations and cardiovascular events in connected dialysis patients
• Digital health support was reviewed by Canaud et al. (Toxins 2024) as a tool to empower patients and enhance care

Regulatory and Infrastructure Considerations

• Post-COVID-19 expansion of telemedicine reimbursement in the U.S. and Europe
• HIPAA/data privacy compliance essential
• Requires reliable internet access — a barrier in rural/low-resource settings

UNIT E — Kidney Transplantation: Immunology, Procedure, and Immunosuppressive Medications

1. Immunology of Transplantation

• HLA (Human Leukocyte Antigens): Class I (HLA-A, B, C) on all nucleated cells; Class II (HLA-DR, DQ, DP) on antigen-presenting cells. HLA mismatch drives the primary rejection response
• ABO blood group antigens: Expressed on vascular endothelium — ABO incompatibility causes hyperacute rejection
• Minor histocompatibility antigens: Can cause chronic rejection despite HLA matching

• Recipients develop pre-formed anti-HLA antibodies (DSA) from prior transfusions, pregnancies, or previous transplants
• Panel Reactive Antibody (PRA) measures the degree of sensitization (% of a panel of donors against whom the recipient has antibodies)
• Crossmatch testing: Donor lymphocytes + recipient serum. Positive crossmatch = high risk of hyperacute rejection; transplantation generally contraindicated

2. Surgical Procedure

• Bilateral native nephrectomy not routinely required
• Bladder preparation (cystoscopy if history of bladder abnormalities)
• Pretransplant evaluation: cardiac workup, infection screening, malignancy screening

1. Retroperitoneal (heterotopic) placement in the right or left iliac fossa — avoids peritoneal cavity
2. Vascular anastomoses:
   • Renal artery → recipient external iliac artery (end-to-side) or internal iliac artery (end-to-end)
   • Renal vein → recipient external iliac vein (end-to-side)
3. Ureteroneocystostomy: Donor ureter implanted into the recipient bladder (Lich-Gregoir or Politano-Leadbetter technique); a double-J stent placed to prevent ureteric complications
4. Native kidneys left in place unless causing complications (hypertension, recurrent infections, polycystic kidneys requiring space)

• Immediate graft function: Urine output within minutes-hours
• Delayed graft function (DGF): Need for dialysis in first week — occurs in ~25% of deceased-donor transplants
• Primary non-function: Graft never functions; rare

3. Immunosuppressive Medications

• Acute cellular rejection: High-dose methylprednisolone (pulse steroids); ATG for steroid-resistant cases
• ABMR: Plasmapheresis + IVIg + rituximab; eculizumab in severe cases

UNIT F — Transplantation Donor Types and Special Situations

1. Living Donor Transplantation

• Living Related Donor (LRD): Biological relative (sibling, parent, child). HLA matching generally better
• Living Unrelated Donor (LURD): Spouse, friend, altruistic stranger. Outcomes comparable to related donors

• Superior outcomes: 5-year graft survival ~85–90% vs. ~75–80% for deceased donors
• No/minimal cold ischemia — warm hand-off possible
• Preemptive transplantation: Can be performed before dialysis initiation — best outcomes
• Elective scheduling: Optimizes recipient preparation

• Complete medical and psychosocial evaluation
• Ensures donor GFR ≥ 80 mL/min/1.73 m² (or age-appropriate predicted post-donation GFR ≥ 45)
• Rules out hypertension, diabetes, proteinuria, urological abnormalities, malignancy
• CT angiography to assess vascular anatomy
• Independent living donor advocate (ILDA) required in most centers to protect donor autonomy

• Laparoscopic donor nephrectomy (LDN) is the standard — less pain, faster recovery vs. open
• Left kidney preferred (longer renal vein)
• Donor long-term outcomes: Modestly increased lifetime risk of ESRD (excess risk ~0.5%) but overall excellent prognosis

2. Deceased Donor (Cadaver) Transplantation

• Brain Death (DBD): Donor with irreversible cessation of all brain function but maintained circulation. Gold standard. Allows optimal organ procurement
• Donation after Circulatory Death (DCD): Donor whose heart has stopped. Two types:
  • Controlled DCD (Maastricht III/IV): Withdrawal of life-sustaining treatment in ICU; planned procurement
  • Uncontrolled DCD (Maastricht I/II): Unexpected cardiac arrest

• Hormonal resuscitation (thyroid hormone, vasopressin, steroids, insulin)
• Hemodynamic optimization prior to procurement
• Minimizing cold ischemia time

• Static cold storage (SCS): Kidney flushed with cold preservation solution (UW solution, HTK solution) and stored on ice
• Machine perfusion (normothermic/hypothermic): Increasingly used for DCD kidneys and marginal donors:
  • Hypothermic Machine Perfusion (HMP): Reduces DGF; perfusion pressure and resistance predict viability
  • Normothermic Machine Perfusion (NMP): Maintains organ at 37°C with oxygenated blood — allows functional assessment before implantation

• Age >60, or age 50–59 with ≥2 of: hypertension, creatinine >1.5 mg/dL, CVA as cause of death
• Kidney Donor Profile Index (KDPI): Score 0–100% predicting relative risk of graft failure; KDPI ≥85% = marginal kidney
• Marginal kidneys still confer survival benefit over remaining on dialysis, especially for older recipients

3. Paired Exchange (Kidney Paired Donation — KPD)

• 2-way exchange: Pair A (donor A → recipient B) and Pair B (donor B → recipient A)
• 3-way/multiway chains: Multiple pairs exchanged simultaneously
• Non-simultaneous Extended Altruistic Donor (NEAD) Chains: An altruistic ("Good Samaritan") donor initiates a chain; the "bridge donor" at the end donates later, extending the chain to benefit additional pairs
  • The longest documented chain involved 16 transplants

• UNOS/AAMC National Kidney Registry (U.S.): Largest national KPD program
• NHS Blood and Transplant (UK): Runs quarterly matching runs
• Computer algorithms (including AI-based matching) maximize the number of compatible pairs found in each run

4. ABO-Incompatible (ABOi) Transplantation

1. Rituximab (anti-CD20): Depletes B-cells to prevent rebound antibody production after plasmapheresis. Administered 2–4 weeks before transplant
2. Antibody removal (pre-transplant, 2 weeks):
   • Plasmapheresis (plasma exchange): Non-specific removal of antibodies and plasma proteins
   • Immunoadsorption (IA): Antigen-specific (ABO antigen columns) or non-specific (protein A). More efficient; preserves clotting factors
3. Target anti-A/B IgG titer: Reduce to ≤1:8 (some centers accept ≤1:16) before transplantation
4. Standard triple maintenance immunosuppression (tacrolimus + MMF + prednisolone)
5. IVIg: Used in some protocols for immunomodulation

• Titer ≤1:8: Rituximab alone
• Titer 1:16–1:64: Rituximab + plasmapheresis
• Titer >1:64: Rituximab + immunoadsorption

• 1-year graft survival: ~90% in experienced centers
• UK data (2001–2012): 5-year graft survival 83% for ABOi vs. 88% for standard living-donor transplants
• Risks: Higher ABMR rates, infection (especially CMV, BK virus), higher costs (~$86,000 additional 3-year cost vs. compatible transplant in U.S.)
• A 2024 study (Naciri Bennani et al., Frontiers in Immunology 2024) confirmed feasibility even with very high titers ≥1:512 — all patients achieved target titers pre-transplant and had stable graft function at 4 years

5. Transplantation in Sensitized Recipients

• Previous transplants (most potent)
• Blood transfusions
• Pregnancies

• Positive crossmatch = contraindication to transplantation with that donor
• Highly sensitized patients have extremely long waiting times (median >7 years in some centers)
• Even after transplant, they remain at high risk for ABMR

• UK data: 5-year graft survival 71% for HLA-incompatible (crossmatch-positive) transplants vs. 88% standard living donor
• Risk of ABMR remains elevated (chronic active ABMR remains the leading cause of late graft loss)
• De novo DSA formation post-transplant (due to inadequate immunosuppression adherence) is a major cause of late failure

Summary Table: Special Transplantation Scenarios

Sources: National Kidney Foundation Primer on Kidney Diseases, 8e; Brenner and Rector's The Kidney, 2-Volume Set; Comprehensive Clinical Nephrology, 7th Edition; CONVINCE RCT (NEJM 2023, PMID 37326323); CONVINCE QoL analysis (Kidney Int 2024, PMID 39089577); Mata-Lima et al. (Nefrologia 2024); Canaud et al. (Toxins 2024); FDA 510(k) clearance of Fresenius 5008X (2024); Naciri Bennani et al. (Front Immunol 2024, PMID 39687613)All four units are now comprehensively covered. Here is a recap of what each section contains:

• Nocturnal dialysis: 6–8 hour overnight sessions; FHN Nocturnal Trial showed improved secondary outcomes (BP, phosphate, weight) but primary composite not met; safety improved by remote monitoring and blood-leak detectors
• Online Hemodiafiltration (OL-HDF): High-volume convective + diffusive therapy; the landmark CONVINCE RCT (NEJM 2023) showed 23% relative mortality reduction vs. high-flux HD; FDA cleared the Fresenius 5008X in 2024 for U.S. use
• Short daily HD: 5–6 sessions/week; FHN Daily Trial met its primary composite (mortality + LV mass); better BP, QoL, phosphate control; requires more frequent vascular access interventions